Tiziana Life Sciences (US) (TLSA) has released an update.
Tiziana Life Sciences reports promising results from its Expanded Access Program, with 70% of multiple sclerosis patients experiencing significant improvements in fatigue after six months of treatment with intranasal foralumab. The study found all participants either stabilized or improved in key clinical measures, indicating a potential new therapeutic option for managing symptoms associated with the disease.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
